01 16Amitiza
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 272
2018 Revenue in Millions : 305
Growth (%) : -11
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 236
2019 Revenue in Millions : 277
Growth (%) : -15
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 189
2019 Revenue in Millions : 209
Growth (%) : -9
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 197
2020 Revenue in Millions : 189
Growth (%) : 4
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 70
2020 Revenue in Millions : 227
Growth (%) : -67
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 159
2021 Revenue in Millions : 197
Growth (%) : -19
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 168
2021 Revenue in Millions : 202
Growth (%) : -17
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 5
2021 Revenue in Millions : 70
Growth (%) : -93
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 157
2022 Revenue in Millions : 168
Growth (%) : -6
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 77
2022 Revenue in Millions : 159
Growth (%) : -51
LOOKING FOR A SUPPLIER?